Progresses on active targeting liposome drug delivery systems for tumor therapy_Journal of Biomedical Engineering

Authors：

ZHANG Manyu , LOU Chenxi ,  CAO Aoneng

Institute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, P. R. China;

Corresponding author：

Keywords：

Liposome; Active targeting; Tumor therapy

DOI：

10.7507/1001-5515.202110067

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Liposome is an ideal drug carrier with many advantages such as excellent biocompatibility, non-immunogenicity, and easy functionalization, and has been used for the clinical treatment of many diseases including tumors. For the treatment of tumors, liposome has some passive targeting capability, but the passive targeting effect alone is very limited in improving the drug enrichment in tumor tissues, and active targeting is an effective strategy to improve the drug enrichment. Therefore, active targeting liposome drug-carriers have been extensively studied for decades. In this paper, we review the research progresses on active targeting liposome drug-carriers based on the specific binding of the carriers to the surface of tumor cells, and summarize the opportunities, challenges and future prospects in this field.

Citation： ZHANG Manyu, LOU Chenxi, CAO Aoneng. Progresses on active targeting liposome drug delivery systems for tumor therapy. Journal of Biomedical Engineering, 2022, 39(3): 633-638. doi: 10.7507/1001-5515.202110067 Copy

1.	Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71(11): 7-33.
2.	Mishra K, Jain A K. Liposomes: an emerging approach for the treatment of cancer. Curr Pharm Des, 2021, 27(20): 2398-2414.
3.	Haider M, Abdin S M, Kamal L, et al. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics, 2020, 12(3): 288.
4.	Klochkov S G, Neganova M E, Nikolenko V N, et al. Implications of nanotechnology for the treatment of cancer: recent advances. Semin Cancer Biol, 2021, 69: 190-199.
5.	Kiaie S H, Mojarad J S, Khaleseh F, et al. Axial pharmaceutical properties of liposome in cancer therapy: recent advances and perspectives. Int J Pharm, 2020, 581: 119269.
6.	Das R P, Gandhi V V, Singh B G, et al. Passive and active drug targeting: role of nanocarriers in rational design of anticancer formulations. Curr Pharm Des, 2019, 25(28): 3034-3056.
7.	Bangham A D, Standish M M, Watkins J C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol, 1965, 13(1): 238-252.
8.	Filipczak N, Pan J, Yalamarty S, et al. Recent advancements in liposome technology. Adv Drug Deliv Rev, 2020, 156: 4-22.
9.	Zhang Y R, Lin R, Li H J, et al. Strategies to improve tumor penetration of nanomedicines through nanoparticle design. Wiley Interdiscip Rev: Nanomed Nanobiotechnol, 2019, 11(1): e1519.
10.	Wilhelm S, Tavares A J, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater, 2016, 1(5): 16014.
11.	Yan W, Leung S S, To K K. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine (Lond), 2020, 15(3): 303-318.
12.	Liu C Y, Ewert K K, Yao W, et al. A multifunctional lipid incorporating active targeting and dual-control release capabilities for precision drug delivery. ACS Appl Mater Interfaces, 2020, 12(1): 70-85.
13.	Jia D L, Yang Y J, Yuan F J, et al. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. Int J Pharm, 2020, 586: 119541.
14.	Silva J D, Fernandes R S, Oda C R, et al. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model. Biomed Pharmacother, 2019, 118: 109323.
15.	Yu S, Bi X J, Yang L, et al. Co-delivery of paclitaxel and PLK1-Targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol, 2019, 15(6): 1135-1148.
16.	Cadinoiu A N, Rata D M, Atanase L I, et al. Aptamer-functionalized liposomes as a potential treatment for basal cell carcinoma. Polymers, 2019, 11(9): 1515.
17.	Duan S L, Yu Y T, Lai C H, et al. Vincristine-loaded and sgc8-modified liposome as a potential targeted drug delivery system for treating acute lymphoblastic leukemia. J Biomed Nanotechnol, 2018, 15(5): 910-921.
18.	Zheng T T, Feng H H, Liu Li, et al. Enhanced antiproliferative effect of resveratrol in head and neck squamous cell carcinoma using GE11 peptide conjugated liposome. Int J Mol Med, 2019, 43(4): 1635-1642.
19.	Wei Y, Song S, Duan N, et al. MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy. Adv Sci (Weinh), 2020, 7(17): 1902746.
20.	Yuan B, Zhao Y, Dong S Y, et al. Cell-penetrating peptide-coated liposomes for drug delivery across the blood-brain barrier. Anticancer Res, 2019, 39(1): 237-243.
21.	Dorjsuren B, Chaurasiya B, YE Z, et al. Cetuximab-coated thermo-sensitive liposomes loaded with magnetic nanoparticles and doxorubicin for targeted EGFR-expressing breast cancer combined therapy. Int J Nanomedicine, 2020, 15: 8201-8215.
22.	Ollila T A, Butera J, Egan P C, et al. Vincristine sulfate liposome injection (VSLI) with bendamustine and rituximab as first-line therapy for indolent B-cell lymphomas: a phase 1 study. Blood, 2020, 136(1): 15-16.
23.	Zhang B, Qi L, Wang X, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond), 2020, 40(12): 711-720.
24.	Moore K N, Bookman M, Sehouli J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol, 2021, 39(17): 1842-1855.
25.	Kojima T, Shah M A, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol, 2020, 38(35): 4138-4148.
26.	Nwahara N, Abrahams G, Prinsloo E, et al. Folic acid-modified phthalocyanine-nanozyme loaded liposomes for targeted photodynamic therapy. Photodiagn Photodyn Ther, 2021, 36: 102527.
27.	Ding J Q, Zhao D, Hu Y W, et al. Terminating the renewal of tumor-associated macrophages: a sialic acid-based targeted delivery strategy for cancer immunotherapy, 2019, 571: 118706.
28.	Ni S J, Zhuo Z J, Pan Y F, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces, 2021, 13(8): 9500-9519.
29.	Kang H Z, O'donoghue M B, Liu H P, et al. A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb), 2010, 46(2): 249-251.
30.	Nsairat H, Mahmoud I S, Odeh F, et al. Grafting of anti-nucleolin aptamer into preformed and remotely loaded liposomes through aptamer-cholesterol post-insertion. RSC Adv, 2020, 10(59): 36219-36229.
31.	Cao Y J, Zhou Y J, Zhuang Q F, et al. Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer. Int J Clin Exp Med, 2015, 8(8): 12182-12191.
32.	Huang X Q, Chen L Z, Zhang Y P, et al. GE11 peptide conjugated liposomes for EGFR-targeted and chemophotothermal combined anticancer therapy. Bioinorg Chem Appl, 2021, 2021: 5534870.
33.	Zhou J Q, Li Y Y, Huang W L, et al. Source and exploration of the peptides used to construct peptide-drug conjugates. Eur J Med Chem, 2021: 113712.
34.	Cheng Y, Ho K, Lin W, et al. Bispecific antibody (HER2 x mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Biomaterials, 2020, 111: 386-397.
35.	Haeri A, Zalba S, Ten Hagen T L, et al. EGFR targeted thermosensitive liposomes: a novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery. Colloids Surf B Biointerfaces, 2016, 146: 657-669.
36.	Yan G H, Wang K, Shao Z X, et al. Artificial antibody created by conformational reconstruction of the complementary-determining region on gold nanoparticles. Proc Natl Acad Sci U S A, 2018, 115(1): E34-E43.
37.	Cao Aoneng. The last secret of protein folding: the real relationship between long-range interactions and local structures. Protein J, 2020, 39(5): 422-433.
38.	曹傲能. 蛋白质结构的“限域下最低能量结构片段”假说与蛋白质进化的“石器时代”. 物理化学学报, 2020, 36(1): 231-240.
39.	Abreu T R, Biscaia M, Gonçalves N, et al. In vitro and in vivo tumor models for the evaluation of anticancer nanoparticles. Bio-Nanomed Cancer Therapy, 2021, 1295: 271-299.
40.	Antoniou A, Giofrè S, Seneci P, et al. Stimulus-responsive liposomes for biomedical applications. Drug Discov Today, 2021, 26(8): 1794-1824.
41.	De Leo V, Milano F, Agostiano A, et al. Recent advancements in polymer/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers (Basel), 2021, 13(7): 1027.

1. Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71(11): 7-33.
2. Mishra K, Jain A K. Liposomes: an emerging approach for the treatment of cancer. Curr Pharm Des, 2021, 27(20): 2398-2414.
3. Haider M, Abdin S M, Kamal L, et al. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics, 2020, 12(3): 288.
4. Klochkov S G, Neganova M E, Nikolenko V N, et al. Implications of nanotechnology for the treatment of cancer: recent advances. Semin Cancer Biol, 2021, 69: 190-199.
5. Kiaie S H, Mojarad J S, Khaleseh F, et al. Axial pharmaceutical properties of liposome in cancer therapy: recent advances and perspectives. Int J Pharm, 2020, 581: 119269.
6. Das R P, Gandhi V V, Singh B G, et al. Passive and active drug targeting: role of nanocarriers in rational design of anticancer formulations. Curr Pharm Des, 2019, 25(28): 3034-3056.
7. Bangham A D, Standish M M, Watkins J C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol, 1965, 13(1): 238-252.
8. Filipczak N, Pan J, Yalamarty S, et al. Recent advancements in liposome technology. Adv Drug Deliv Rev, 2020, 156: 4-22.
9. Zhang Y R, Lin R, Li H J, et al. Strategies to improve tumor penetration of nanomedicines through nanoparticle design. Wiley Interdiscip Rev: Nanomed Nanobiotechnol, 2019, 11(1): e1519.
10. Wilhelm S, Tavares A J, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater, 2016, 1(5): 16014.
11. Yan W, Leung S S, To K K. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine (Lond), 2020, 15(3): 303-318.
12. Liu C Y, Ewert K K, Yao W, et al. A multifunctional lipid incorporating active targeting and dual-control release capabilities for precision drug delivery. ACS Appl Mater Interfaces, 2020, 12(1): 70-85.
13. Jia D L, Yang Y J, Yuan F J, et al. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. Int J Pharm, 2020, 586: 119541.
14. Silva J D, Fernandes R S, Oda C R, et al. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model. Biomed Pharmacother, 2019, 118: 109323.
15. Yu S, Bi X J, Yang L, et al. Co-delivery of paclitaxel and PLK1-Targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol, 2019, 15(6): 1135-1148.
16. Cadinoiu A N, Rata D M, Atanase L I, et al. Aptamer-functionalized liposomes as a potential treatment for basal cell carcinoma. Polymers, 2019, 11(9): 1515.
17. Duan S L, Yu Y T, Lai C H, et al. Vincristine-loaded and sgc8-modified liposome as a potential targeted drug delivery system for treating acute lymphoblastic leukemia. J Biomed Nanotechnol, 2018, 15(5): 910-921.
18. Zheng T T, Feng H H, Liu Li, et al. Enhanced antiproliferative effect of resveratrol in head and neck squamous cell carcinoma using GE11 peptide conjugated liposome. Int J Mol Med, 2019, 43(4): 1635-1642.
19. Wei Y, Song S, Duan N, et al. MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy. Adv Sci (Weinh), 2020, 7(17): 1902746.
20. Yuan B, Zhao Y, Dong S Y, et al. Cell-penetrating peptide-coated liposomes for drug delivery across the blood-brain barrier. Anticancer Res, 2019, 39(1): 237-243.
21. Dorjsuren B, Chaurasiya B, YE Z, et al. Cetuximab-coated thermo-sensitive liposomes loaded with magnetic nanoparticles and doxorubicin for targeted EGFR-expressing breast cancer combined therapy. Int J Nanomedicine, 2020, 15: 8201-8215.
22. Ollila T A, Butera J, Egan P C, et al. Vincristine sulfate liposome injection (VSLI) with bendamustine and rituximab as first-line therapy for indolent B-cell lymphomas: a phase 1 study. Blood, 2020, 136(1): 15-16.
23. Zhang B, Qi L, Wang X, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond), 2020, 40(12): 711-720.
24. Moore K N, Bookman M, Sehouli J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol, 2021, 39(17): 1842-1855.
25. Kojima T, Shah M A, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol, 2020, 38(35): 4138-4148.
26. Nwahara N, Abrahams G, Prinsloo E, et al. Folic acid-modified phthalocyanine-nanozyme loaded liposomes for targeted photodynamic therapy. Photodiagn Photodyn Ther, 2021, 36: 102527.
27. Ding J Q, Zhao D, Hu Y W, et al. Terminating the renewal of tumor-associated macrophages: a sialic acid-based targeted delivery strategy for cancer immunotherapy, 2019, 571: 118706.
28. Ni S J, Zhuo Z J, Pan Y F, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces, 2021, 13(8): 9500-9519.
29. Kang H Z, O'donoghue M B, Liu H P, et al. A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb), 2010, 46(2): 249-251.
30. Nsairat H, Mahmoud I S, Odeh F, et al. Grafting of anti-nucleolin aptamer into preformed and remotely loaded liposomes through aptamer-cholesterol post-insertion. RSC Adv, 2020, 10(59): 36219-36229.
31. Cao Y J, Zhou Y J, Zhuang Q F, et al. Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer. Int J Clin Exp Med, 2015, 8(8): 12182-12191.
32. Huang X Q, Chen L Z, Zhang Y P, et al. GE11 peptide conjugated liposomes for EGFR-targeted and chemophotothermal combined anticancer therapy. Bioinorg Chem Appl, 2021, 2021: 5534870.
33. Zhou J Q, Li Y Y, Huang W L, et al. Source and exploration of the peptides used to construct peptide-drug conjugates. Eur J Med Chem, 2021: 113712.
34. Cheng Y, Ho K, Lin W, et al. Bispecific antibody (HER2 x mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Biomaterials, 2020, 111: 386-397.
35. Haeri A, Zalba S, Ten Hagen T L, et al. EGFR targeted thermosensitive liposomes: a novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery. Colloids Surf B Biointerfaces, 2016, 146: 657-669.
36. Yan G H, Wang K, Shao Z X, et al. Artificial antibody created by conformational reconstruction of the complementary-determining region on gold nanoparticles. Proc Natl Acad Sci U S A, 2018, 115(1): E34-E43.
37. Cao Aoneng. The last secret of protein folding: the real relationship between long-range interactions and local structures. Protein J, 2020, 39(5): 422-433.
38. 曹傲能. 蛋白质结构的“限域下最低能量结构片段”假说与蛋白质进化的“石器时代”. 物理化学学报, 2020, 36(1): 231-240.
39. Abreu T R, Biscaia M, Gonçalves N, et al. In vitro and in vivo tumor models for the evaluation of anticancer nanoparticles. Bio-Nanomed Cancer Therapy, 2021, 1295: 271-299.
40. Antoniou A, Giofrè S, Seneci P, et al. Stimulus-responsive liposomes for biomedical applications. Drug Discov Today, 2021, 26(8): 1794-1824.
41. De Leo V, Milano F, Agostiano A, et al. Recent advancements in polymer/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers (Basel), 2021, 13(7): 1027.

Previous Article
Drugs and hepatitis B virus reactivation
Next Article
Research advances of three-dimensional bioprinting technology in urinary system tissue engineering

Journal of Biomedical Engineering

Progresses on active targeting liposome drug delivery systems for tumor therapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content